anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide dosing regimens effective for neural stem cell proliferating agents and neural stem cell differentiating agents, to provide a kit including the regimens, and to provide uses of the kit.  <P>SOLUTION: The dosing regimens effective for neural stem cell proliferating agents and neural stem cell differentiating agents, the kit including the regimens, and uses of the kit, are provided. Such a kit or method may treat neurodegenerative diseases or conditions through short-term or long-term uses. Further, related compositions and methods may continuously or intermittently use for various kinds of regimens. In particular, the thus provided kit is intended for treating or ameliorating neurodegenerative diseases or conditions in mammals and includes EPO and at least 3 dose-units of hCG or LH.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A method of providing an aesthetic effect on a keratinous substrate, for example human skin, comprising applying a chromic composition to the substrate of a subject, the chromic composition comprising a colourant and optionally a pigment or dye, the colourant changing colour upon being subjected to a stimulus. Preferably, the stimulus is heat or light, e.g. the colourant is a thermochromic liquid crystal or a thermochromic- or photochromic- leuco colourant. Preferably, thermochromic colourants change colour in the range 25 °C to 37 °C. Preferably, the composition is sprayable. The composition may comprise any of water, a volatile solvent, a film-forming component and a rheology modifier (e.g. polyethylene glycol). Also claimed are compositions suitable for application to a keratinous substrate (e.g. skin) comprising a colourant comprising a liquid crystal and/or a leuco dye. Further claimed is a sprayable chromic composition comprising a chromic composition comprising a UV or heat responsive colourant dispersed in a base composition wherein the base composition comprises a film-forming component and a carrier.
BACKGROUND: Esophagectomy for esophageal cancer has a complication rate of up to 60%. Prediction models could be helpful to preoperatively estimate which patients are at increased risk of morbidity and mortality. The objective of this study was to determine the best prediction models for morbidity and mortality after esophagectomy and to identify commonalities among the models.
PATIENTS AND METHODS: A systematic review was performed in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and was prospectively registered in PROSPERO ( https://www.crd.york.ac.uk/prospero/ , study ID CRD42022350846). Pubmed, Embase, and Clarivate Analytics/Web of Science Core Collection were searched for studies published between 2010 and August 2022. The Prediction model Risk of Bias Assessment Tool was used to assess the risk of bias. Extracted data were tabulated and a narrative synthesis was performed.
RESULTS: Of the 15,011 articles identified, 22 studies were included using data from tens of thousands of patients. This systematic review included 33 different models, of which 18 models were newly developed. Many studies showed a high risk of bias. The prognostic accuracy of models differed between 0.51 and 0.85. For most models, variables are readily available. Two models for mortality and one model for pulmonary complications have the potential to be developed further.
CONCLUSIONS: The availability of rigorous prediction models is limited. Several models are promising but need to be further developed. Some models provide information about risk factors for the development of complications. Performance status is a potential modifiable risk factor. None are ready for clinical implementation.
FIELD: veterinary medicine. SUBSTANCE: invention is designed for specific prophylactics of animal infection diseases. Tuberculosis mycobacteria are grown and then destroyed. To that end, formalin is added to culture liquid in two steps: first to formalin concentration 0.3-0.4%, after which mixture is incubated for 7-10 days at 37-40 C, and then to final formalin concentration 0.5-0.6%, after which incubation at 44-46 C is carried out for 5-8 days. Destruction of mycobacteria is effected by  60 Co gamma- radiation in dose (1.0-2.0) x 10 6  R. When detoxification of culture liquid is completed, aluminum hydroxide is added. Resulting mixture is centrifuged or settled, precipitate is collected, bagged, and autoclaved. EFFECT: increased anatoxin storage time to 3-5 years. 2 cl, 4 ex
### Premature Closure of Fetal Ductus Arteriosus

Avoid use of NSAIDs, including mefenamic acid, in pregnant women at about 30 weeks gestation and later. NSAIDs including mefenamic acid, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

### Oligohydramnios/Neonatal Renal Impairment

Use of NSAIDs, including mefenamic acid, at about 20 weeks gestation or later in pregnancymay cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit mefenamic acid use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if mefenamic acid treatment extends beyond 48 hours. Discontinue mefenamic acid if oligohydramnios occurs and follow up according to clinical practice [ see Precautions; Pregnancy].
<P>PROBLEM TO BE SOLVED: To provide BAFF-R for therapeutic use capable of being clearly characterized and having a glycosylation pattern avoiding aggregation in eucaryocytes with maintaining specificity and affinity to BAFF.  <P>SOLUTION: A BAFF-R glycoprotein which is a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain resulting in an altered O-linked glycosylation pattern is provided. Methods and pharmaceutical compositions for treating disorders mediated with B-cells and T-cells are also provided. Ligands of TNF family, receptors and antagonists thereof and agonists, and use thereof for regulating immune responses are also provided. Partially, those depend on discovery and characterization of glycosylation patterns of human BAFF-R and variants thereof.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Sugar pill 5, 10 or 20 mg tablet, orally, daily. Sugar pill dosage will be titrated per blood pressure results.
Aplasia cutis congenita (ACC) is a group of rare heterogeneous disorders characterised by absent areas of skin at birth. The majority of cases involve the scalp region. ACC limited to one lower limb is extremely rare. We report an usual case of ACC limited to the left thigh of which healing occurred in utero. The case was managed conservatively and the disease course has been favourable with no limitations in limb function and an entirely normal development. Most cases of ACC are self-healing, justifying a conservative approach. This holds further true for ACC limited to one lower limb where the majority of cases reported to date show a favourable disease course with minimal conservative treatment.
An interactive intuitive method of forming a 3D dose distribution during optimization of IMRT planning is disclosed. New techniques for providing a user friendly interface are described herein for adjusting dose distribution values during optimization of radiation application planning. In one embodiment, a graphical user interface is provided that provides an image of a target region for a radiation application and a graphical overlay of a dose distribution disposed on the target region that visually represents a planned dose distribution according to an entered dose parameter. In one or more embodiments, the dose distribution may be automatically calculated from input parameters provided by the user through a graphical user interface prior to optimization. A user (e.g. a clinician, radiation oncologist or radiation therapy operator, etc.) can modify the visualization of the dose distribution volume via a user input device in combination with a graphical user interface during optimization and cause the modification to be adjusted in real time.
NEW MATERIAL:A peptide of formula (B is H, methionyl; Cys is residue of cysteine; X1 residue of 5-9 aminoacids; X2 is residue of one aminoacid; X3 is resiue of 138-148 aminoacids). USE:Antiviral, cell growth inhibitor: it has not only high antiviral activity but also cell growth inhibiting and NK-cell stimulating activity. PREPARATION:The peptide of the formula is synthesized by the solid phase method, one of chemical synthetic method of peptides. The carboxyl group of an aminoacid bearing a protected alpha-amino group is bonded to a support such as a polystyrene resin crosslinked with divinylbenzene and the amino-protecting groups are selectively removed. The second aminoacid having a protected alpha- amino group is made to react with the fee amino group and the operation is repeated until the objective peptide is formed. Finally, the covalent bond between the carboxyl group of the terminal aminoacid in the peptide and the resin is broken.
The invention discloses an extracting and purifying method of lutein from pellet algae in the biological technical domain, which comprises the following steps: extracting lutein and ester through composite agent; using 5-20% sodium hydroxide to saponify; rotating; evaporating; washing; crystallizing; obtaining high-purity lutein crystal; weighing 0. 2-2g algae powder to place in the 50-500ml centrifuge tube; adding 8. 0-80. 0ml composite liquid solvent to extract under 10-40 deg. c for 0. 5-2h; adding 10-100ml 5%-30% sodium hydroxide solution into the test tube with hybrid extractant; saponifying at 30-70 deg. c for 3-8h; centrifuging under low temperature for 5-10 min; extracting the product from organic phase. The invention ensures the optimum saponifying technique, which is extracted from pellet algae cell effectively.
Methods and systems are presented for analyzing the blood of a living being. Equations are presented for volume-aware extension of the concept of Hematocrit. A method for calculating these volume-aware measures and using said measures to evaluate and guide possible treatments is described. A system comprising an automated analyzer and a processor and other components is described which can carry out said calculations. Methods of treatment for volume abnormalities are described which are guided by the volume-aware Hct measures. In one exemplary embodiment, a method of treatment for plasma volume excess using ultrafiltration is described. In another exemplary embodiment, a method of treatment for red cell volume excess using erythrocytapheresis is described.
FIELD: fodder production.SUBSTANCE: invention relates to fodder production, in particular, to a method for production of fodder soya-maize substrate intended for probiotic crops growing. Method involves boiling, filtration and sterilization. Soya beans and maize grains are soaked for 12 hours in separate containers. Then soya beans are cleaned of husks and milled, and maize grains are washed and also ground to a gusty condition, water is added to volume of one liter into a container with milled soya beans and into a container with milled maize grains and boiled for 20 minutes at temperature of 100–110 °C. Obtained soya and maize broths are cooled to 37–40 °C, filtered, sterilized in autoclave for 20 minutes at temperature of 121 °C and pressure of 1.1 atm and mixed at ratio of 1:5, where one part is maize broth and 5 parts of soya broth and a substrate is obtained. Probiotic microorganisms are added to obtained substrate.EFFECT: use of the invention enables to obtain a nutrient medium providing a storage effect and intensive growth of probiotic cultures.1 cl
The primary purpose of the study is to evaluate the distribution of radiopaque microspheres loaded with doxorubicin in the treatment of unresectable HCC. Prospective, single arm, open label, single centre, pilot study. All patients will undergo clinical follow-up. Twenty patients will be enrolled. Primary endpoint : Local response (evaluated with CT and MRI at 4 to 6 weeks post each procedure and at 6 months according to mRECIST) in patients with intermediate-stage HCC following chemoembolisation with radiopaque bead. Secondary endpoints include: 1) Better definition of end point of embolization for drug eluting beads : Ability to achieve near-stasis during chemoembolisation procedure in the tumour feeding vessels using intra-procedural imaging feedback from the radiopaque bead (early visualization of non target embolization 2) Total dose needed for tumor devascularization 3)Distribution of radiopaque beads and correlation with necrosis and adverse events
Patients receive lenalidomide PO daily on days 1-21 and pidilizumab IV over 1-2 hours on day 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PURPOSE: To prepare an aqueous solution for ophthalmic use comprising a specific amount of stabilized chlorine dioxide as a preservative. CONSTITUTION: This aqueous solution is prepared by including chlorine dioxide stabilized as a preservative in an amount of about 0.002-0.02% (wt./vol.), preferably about 0.004-0.01% (wt./vol.)in an aqueous solution for ophthalmic use. Furthermore, about 0.5-0.9% (wt./vol.) ophthalmically permissible inorganic salt (e.g. an alkaline metallic chloride or an alkaline earth metallic chloride) and a buffer agent (e.g. potassium phosphate, boric acid, sodium borate or sodium phosphate) in an amount effective in stabilizing the aqueous solution at a permissible physiological pH (about 6.8-8) are contained in the aqueous solution.
Very low birth weight (VLBW) preterm infants (birth weight \< 1,500g) sustain a high risk of neuromotor disability, as exemplified by delayed walking attainment. Spontaneous kicking and supported stepping have been proposed as the early precursors to independent walking. The continuity of these early leg movements with independent walking has been established in normal term infants, but such relations remain unclear in VLBE premature infants. Therefore, the purposes of this one-year follow-up study are twofold: (1) to prospectively examine the spontaneous kicking and the supported stepping movement in VLBW premature infants until attainment of independent walking; and (2) to assess factors (i.e. gross motor development, cardiopulmonary function, anthropometry, body composition and cognition) that could potentially influence walking attainment in VLBW premature infants. This study will enroll 15 VLBW premature infants born at National Taiwan University Hospital. Infants will be scheduled for spontaneous kicking examination at 2 and 4 months of corrected age, followed by supported stepping examination at 9 and 11 months of corrected age and recorded their age of walking attainment. Age of walking attainment is defined as the time when the child is first able to move for five successive steps without support. At each visit, infants will be examined for spontaneous kicking or supported stepping movements (with three-dimensional kinematic analysis of Peak Motion Analysis System), gross motor function (with the Alberta Infant Motor Scale), cardiopulmonary function (with a pulsed oxymeter), anthropometry (with scale and tape measure), body composition (with the Pediatric Plicometric System) and cognition (with the Chinese Child Development Inventory- Cognitive Subscale). The results of this study will provide important information to help reveal the maturation process of early leg movements prior to walking attainment in premature infants. Furthermore, the identified early neuromotor markers and influencing factors for walking attainment will provide physical therapists useful guidance in making early treatment plans for those premature infants who will develop motor delays.
A complete treatment cycle defined as 28 days or 4 weeks (+/- 2 days). Patients receive a single daily oral dose of 500 mg of dovitinib for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule).
This randomized Control trial will be conducted at Islam central hospital, Sialkot over a duration of 7 months after approval of synopsis. 36 Participants who meet the inclusion criteria will be further divided into 2 groups. The treatment will be given with the frequency of 3 times per week for 6 weeks. Treatment sessions will be of 30 minutes with short resting intervals. Data will be collected using various assessment tools including, berg balance scale, time-up and stroke-specific quality of life. Pre-intervention assessment will be conducted before starting the treatment protocol and post assessment after 6 weeks of treatment. The data will be analyzed using SPSS version 28 for Windows software. Statistical significance will be set at p = 0.05. Normality of data will be assessed through Kolmogorov Smirnov test. Difference between pre-treatment and post-treatment readings will be calculated using Paired sample t-test for parametric data. For non-parametric data Wilcoxon test will be used. Independent sample t-test will be used for parametric data and Mann Whitney test will be used for non-parametric data.
Atopic dermatitis (AD) is a chronic inflammatory skin disease where Th2-type immune responses are dominant. In the lesional skin of AD, keratinocytes show differentiation defects and secrete proinflammatory cytokines and chemokines, amplifying Th2-type responses in AD. We previously reported that inducible loss of B-cell lymphoma 6 (Bcl6), a transcription repressor and a master transcriptional regulator of follicular helper T cells and germinal center B cells, in the whole body results in upregulation of Th2-related cytokines in mouse skin. However, the role of Bcl6 in keratinocytes remains to be clarified. Here, we observed that BCL6 positively regulates the expression of keratinocyte differentiation markers and plasma membrane localization of adherence junctional proteins in keratinocyte cell culture. Although keratinocyte-specific loss of Bcl6 alone did not induce AD-like skin inflammation, it aggravates MC903-induced AD-like skin inflammation in mice. In addition, Bcl6 expression is decreased in the epidermis of lesional skin from MC903-induced AD-like skin inflammation in mice. These results strongly suggest that Bcl6 downregulation in keratinocytes contributes to the development and aggravation of AD-like skin inflammation in mice.
Active intervention (including both pain education and home exercises). A 60-minutes education session will be provided, concerning pain mechanisms and management and a demonstration of the exercises to perform individually at home. Home exercises will be performed daily. To support patients during the treatment, a booklet will be created. One 30-minutes booster session will be planned after 4 weeks. Patients will follow this active intervention for 8 weeks.
Metagenomic next-generation sequencing (mNGS) is an unbiased and rapid method for detecting pathogens. This study enrolled 145 suspected severe pneumonia patients who were admitted to the Affiliated Hospital of Jining Medical University. This study primarily aimed to determine the diagnostic performance of mNGS and conventional microbiological tests (CMTs) using bronchoalveolar lavage fluid samples for detecting pathogens. Our findings indicated that mNGS performed significantly higher sensitivity (97.54% vs 28.68%, P < 0.001), coincidence (90.34% vs 35.17%, P < 0.001), and negative predictive value (80.00% vs 13.21%, P < 0.001) but performed lower specificity than CMTs (52.17% vs 87.5%, P < 0.001). Streptococcus pneumoniae as the most common bacterial pathogen had the largest proportion (22.90%, 30/131) in this study. In addition to bacteria, fungi, and virus, mNGS can detect a variety of atypical pathogens such as Mycobacterium tuberculosis and non-tuberculous. Mixed infections were common in patients with severe pneumonia, and bacterial-fungal-viral-atypical pathogens were the most complicated infection. After adjustments of antibiotics based on mNGS and CMTs, the clinical manifestation improved in 139 (95.86%, 139/145) patients. Our data demonstrated that mNGS had significant advantage in diagnosing respiratory tract infections, especially atypical pathogens and fungal infections. Pathogens were detected timely and comprehensively, contributing to the adjustments of antibiotic treatments timely and accurately, improving patient prognosis and decreasing mortality potentially.IMPORTANCEMetagenomic next-generation sequencing using bronchoalveolar lavage fluid can provide more comprehensive and accurate pathogens for respiratory tract infections, especially when considering the previous usage of empirical antibiotics before admission or complicated clinical presentation. This technology is expected to play an important role in the precise application of antimicrobial drugs in the future.
This will be an open label study of midazolam (dose 2 mg orally, Day 1) followed by midazolam (2 mg orally) given after dosing with intravenous F901318 4 mg/kg bid for one day followed by 2.5 mg/kg bid for 7 doses (Day 7). Up to twenty subjects will be included in two cohorts which will undergo the same dosing schedules of midazolam and F901318 and undergo the same procedures. The first cohort will consist of 12 subjects studied in two groups of six subjects each. If there is clearly a difference in midazolam kinetics detectable between the first and second doses of midazolam, in this first cohort, the second cohort will not be studied. If there is no clear difference, the second cohort will also be studied to give a final result. PK sampling for midazolam and 1- and 4-hydroxymidazolam plasma and urine concentrations will continue for up to and including 24 hours after dosing with midazolam on both occasions. PK sampling for F901318 will continue from before the first dose and up to 24 hours after the ninth dose. A follow up visit will be conducted 7 +/- 2 days after discharge from the clinical unit following completion of blood sampling following the second dose of midazolam and the ninth dose of F901318.
According to one embodiment, a system includes one or more processors operable to determine a plurality of individuals associated with a first health service provider. The processors are further operable to determine a plurality of second health service providers that are each associated with at least one of the individuals, and determine a status associated with each of the individuals. The processors are further operable to generate and communicate for display an image based on the individuals, the second health service providers, and the statuses associated with the individuals. The image comprises a plurality of sections that each represent one of the individuals. Each section includes an indication in the section of the status associated with the one of the individuals. The image further comprises a plurality of groupings of one or more of the sections. Each grouping represents one of the second health service providers.
PURPOSE: A human DCC1(defective in sister chromatid cohesion 1 homolog)-specific monoclonal antibody is provided to diagnose colorectal cancer and to identify DCC1 molecular physiological function. CONSTITUTION: A monoclonal antibody having human DCC1 specificity is prepared by hybridoma cell(deposit number: KCTC 11611BP). A composition for diagnosing colorectal cancer contains the monoclonal antibody. A kit for diagnosing colorectal cancer contains the composition. A protein chip for diagnosing colorectal cancer contains the monoclonal antibody. The monoclonal antibody is arranged on the predetermined site on a substrate and is fixed in high density.